As part of a restructuring of the company’s research and development areas, Tokyo-based Daiichi Sankyo announced the closing of the Plexxikon R&D subsidiary in South San Francisco.
Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC).
Cambridge-based Magenta Therapeutics entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics.
AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.
Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.
Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.
The U.S. FDA placed a hold on Seattle Genetics’ Investigational New Drug Application for vadastuximab talirine.
Seattle Genetics halted all clinical trials of its vadastuximab talirine due to higher incidents of death associated with the treatment for AML patients.